Our US offices are representing CeloNova BioSciences, Inc. (CeloNova) in the sale of its interventional radiology business to Boston Scientific Corporation. The transaction consists of an upfront payment of US$70 million and additional amounts contingent on regulatory and sales milestones.
The engagement resulted from the firm's long standing relationship with CeloNova's general counsel.
US Head of Business Daryl Lansdale (San Antonio) leads a global team of transactional lawyers comprised of Bryan Wittman (San Antonio), Andres Liivak (New York), Nils Rahlf and Christoph Naumann (Frankfurt). Cori Annapolen Goldberg (New York) is leading the firm's FDA efforts. Steve Kuntz (Houston) and Tino Duttine (Frankfurt) lead the firm's tax team and Dan Wellington, Luke McFarland (Washington, DC), Christian Filippitsch and Maria de Lasala Lobera (Brussels) lead the firm's antitrust efforts.
CeloNova BioSciences, Inc., headquartered in San Antonio, Texas, is a global medical device company that develops, manufactures and markets a family of Interventional Cardiology and Endovascular products. CeloNova's products are developed in California and Germany and are currently available in more than 50 countries.
The transaction is expected to close by year end 2015.